LXEO Key Statistics, Chart & Performance
The current stock price of LXEO is 9.15 USD. In the past month the price increased by 19.35%. In the past year, price increased by 36.21%.
LXEO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.3 | 405.81B | ||
| AMGN | AMGEN INC | 14.98 | 176.38B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 151.30B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.05 | 114.72B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.21 | 81.40B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.41 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.17B | ||
| NTRA | NATERA INC | N/A | 31.38B | ||
| BIIB | BIOGEN INC | 10.54 | 25.88B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.63 | 21.17B | ||
| INCY | INCYTE CORP | 15.68 | 19.76B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.33B |
Related stock screener links
About LXEO
Company Profile
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The company is headquartered in New York City, New York and currently employs 72 full-time employees. The company went IPO on 2023-11-03. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Company Info
LEXEO THERAPEUTICS INC
345 Park Avenue South, Floor 6
New York City NEW YORK US
Employees: 72
Phone: 12125479879
LEXEO THERAPEUTICS INC / LXEO FAQ
What does LXEO do?
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The company is headquartered in New York City, New York and currently employs 72 full-time employees. The company went IPO on 2023-11-03. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Can you provide the latest stock price for LEXEO THERAPEUTICS INC?
The current stock price of LXEO is 9.15 USD. The price decreased by -7.85% in the last trading session.
Does LXEO stock pay dividends?
LXEO does not pay a dividend.
What is the ChartMill rating of LEXEO THERAPEUTICS INC stock?
LXEO has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is LXEO stock listed?
LXEO stock is listed on the Nasdaq exchange.
What is the ownership structure of LEXEO THERAPEUTICS INC (LXEO)?
You can find the ownership structure of LEXEO THERAPEUTICS INC (LXEO) on the Ownership tab.
What is the outstanding short interest for LEXEO THERAPEUTICS INC?
The outstanding short interest for LEXEO THERAPEUTICS INC (LXEO) is 10.44% of its float.
LXEO Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to LXEO. When comparing the yearly performance of all stocks, LXEO is one of the better performing stocks in the market, outperforming 93.16% of all stocks.
LXEO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LXEO. While LXEO seems to be doing ok healthwise, there are quite some concerns on its profitability.
LXEO Financial Highlights
Over the last trailing twelve months LXEO reported a non-GAAP Earnings per Share(EPS) of -2.7. The EPS increased by 14.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -72.97% | ||
| ROE | -86.87% | ||
| Debt/Equity | 0 |
LXEO Forecast & Estimates
16 analysts have analysed LXEO and the average price target is 19.79 USD. This implies a price increase of 116.26% is expected in the next year compared to the current price of 9.15.